VistaGen Therapeutics

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression, and other central nervous system disorders. Its portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder, PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD), and AV-101, which the company is developing for the treatment of MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia, and epilepsy. The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

VistaGen Therapeutics reports Q1 loss, focuses on FDA approval

VistaGen Therapeutics faces financial challenges with increased expenses but shows strength in its innovative drug candidates targeting mental health disorders. The company's opportunities lie in FDA approval for fasedienol and market expansion for its pherine drug candidates.

VistaGen reports positive trial results and financial stability in Q2

VistaGen Therapeutics showcased positive trial results and financial stability, emphasizing the potential of their pherine pipeline to create value and improve lives.
While facing challenges such as increased expenses and operational concerns, the company's commitment to advancing treatments presents opportunities for growth and market expansion.
Analyst interest in study details and timelines reflects investor confidence in VistaGen's research programs and potential market impact.
Overall, VistaGen's Q2 performance highlights progress in lead programs and a solid financial foundation for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

VistaGen Therapeutics Inc (NASDAQ: VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investigational pherine nasal spray.

VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B

The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) increased by 9.3% on Friday, May 21. This is why it happened.

VTGN Stock Price: 9.3% Increase Explanation

Iterum Therapeutics Plc

Marker Therapeutics Inc

Sesen Bio Inc.

Tellurian

Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now

SOUTH SAN FRANCISCO, Calif., May 20, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will present at the following investor conferences in June:

VistaGen Therapeutics to Present at Two Investor Conferences in June

The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) increased by over 14% pre-market. This is why it happened.

Vistagen Therapeutics (VTGN) Stock: Over 14% Increase Pre-Market Explanation

Atossa Genetics

Citius Pharmaceuticals

Penny stocks present opportunities to buy the dip often; is that the case with these biotech stocks? The post Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?

Hot Penny Stocks to Watch; Is it Time to Buy The Biotech Dip?

BIOLASE

Ault Global Holdings

Penny stock watchlists? Why they're not as complicated as they seem The post Penny Stocks Watchlists and How to Make One appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Watchlists and How to Make One

The COVID-19 pandemic has exacerbated mental health issues and is triggering new conditions for people already suffering from mental illnesses and substance abuse.  Social anxiety disorder (SAD) is one of the most prevalent mental health conditions in the U.S., affecting 20 million Americans.

Novel Anxiety and Depression Approach by VistaGen Therapeutics

VistaGen has had a tumultuous history, but recent trials have seen success. They may start phase 3 trials for PH94B in May.

VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, announced today that data highlighting the proposed mechanism of action (MOA) of its Phase 3 investigational drug candidate, PH94B nasal spray, were recently presented in a poster session at the Anxiety and Depression Association of America's 2021 Virtual Annual Conference. PH94B is designed with potential to provide rapid-onset acute treatment of anxiety for millions of individuals suffering from social anxiety disorder (SAD) without directly activating gamma-amino butyric acid (GABA-A) receptors. PH94B's MOA is, therefore, fundamentally differentiated from the MOA of benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. Among VistaGen's core goals is for PH94B to displace these and other widely-used but highly-addictive benzodiazepines in the acute treatment paradigm for SAD and other anxiety disorders and phobias.

VistaGen's Poster Presentation at the Anxiety and Depression Association of America's 2021 Annual Conference Differentiates PH94B's Mechanism of Action from Highly-Addictive Benzodiazepines

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen's Chief Executive Officer, will participate in the following investor conferences in March:

VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March

PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders PH10 may have stand-alone potential to displace current oral antidepressants in the drug treatment paradigm for depression disorders

VistaGen's PH10 Nasal Spray Demonstrates Different Mechanism of Action from Benzodiazepines in Preclinical Study

Cenovus Energy

Infinity Pharma

Ardmore Shipping

Charah Solutions Inc

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Stocks to Buy Now Trading Under $10 With Ample Upside Potential

An analyst is very bullish about the biotech.

Why VistaGen Therapeutics Stock Is Soaring Today

The stock price of Vistagen Therapeutics Inc (NASDAQ: VTGN) has increased by over 13% pre-market as of 7:01 AM ET. This is why it happened.

VTGN Stock Price Increases Over 13% Pre-Market: Why It Happened

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and -4.85%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Lags Revenue Estimates

Multiple clinical studies anticipated to launch in Calendar 2021, notably pivotal Phase 3 clinical studies of PH94B as a potential acute treatment of anxiety in adults with social anxiety disorder (SAD)

VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a generation of novel medicines for anxiety, depression, and other central nervous system disorders, primarily through nasal sprays. VistaGen has three therapeutics in their pipeline across 14 indications. VistaGen's lead therapeutic, PH94B, is an FDA-fast-tracked neuroactive nasal spray aiming to initiate recruitment for a Phase 3 in 2Q2021.

VistaGen: Patience Could Lead To Significant Upside

Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review Dr. Louis Monti, VistaGen's Newly-Appointed Vice President, Translational Medicine, and Dr. Michael Liebowitz, VistaGen CNS Clinical and Regulatory Advisory Board Member, Collaborate on Review

VistaGen Announces Publication in CNS Spectrums Detailing Proposed Mechanism of Action of Its Investigational Neuroactive Nasal Sprays for Anxiety and Depression Disorders

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2020 (GLOBE NEWSWIRE) --  VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (“VistaGen”), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its $100 million underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen.

VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering

BioCryst Pharmaceuticals

Teladoc

VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.

Why BioCryst, VistaGen And Teladoc Are Moving Today

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering consisting of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the “Common Stock”), and 2,000,000 shares of its Series D convertible preferred stock (“Series D Preferred Stock”) at a public offering price of $21.16 per share.

VistaGen Therapeutics Announces Pricing of Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 17, 2020 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that it commenced an underwritten public offering of units consisting of its common stock, par value $0.001 per share (the “Common Stock”), and its Series D convertible preferred stock (the “Series D Preferred Stock”). All securities to be sold in the offering are to be sold by VistaGen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

VistaGen Therapeutics Announces Proposed Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today reported its financial results for the fiscal...

VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc.

News for VistaGen Therapeutics Stock (VTGN)